摘要
目的：观察和评价紫杉醇和顺铂联合同步放疗冶疗Ⅲ期非小细胞肺癌的疗效和不良反应。方法：99例Ⅲ期非小细胞肺癌患者随机分为2个组，放疗组（49例）采用常规分割，总剂量66～70Gy，6～7周完成；化放组（50例）采用化疗联合同步放疗，化疗采用紫杉醇加顺铂方案：紫杉醇175mg／（m^2d），d1、8，DDP20～25mg／（m^2d），d2～5，每4周为一疗程。在放疗同时或前后用药，一般4～6个周期。结果：完全缓解率化放组、放疗组分别为28％、14．2％，病情进展率分别为10％，16．3％。2组近期疗效差异无显著性意义（x^2=3．48，P=0．154）。1、3、5年生存率化放组和放疗组分别为63．2％和51．8％，23．6％和9．2％，10．2％和7．4％。中位生存期分别为8、12个月，两组差异有显著性意义（x^2=4．23，P=0．038）。副反应化放组大于放疗组，但可以耐受。结论：紫杉醇和顺铂联合同步常规分割放疗能明显提高Ⅲ期非小细胞肺癌的生存率，副反应增大，但不影响治疗的正常进行。
Objective：To study the clinical efficacy and toxicity of paclitaxel plus cisplatin concimined with radio- therapy in treatment of stage - Ⅲ non -smal- cell lung cancer. Methods： From February 1999 to August 2000,99 patients with stage Ⅲ non - smal - ceil lung cancer were randomized devided into two groups： radiotherapy alone group （49 patients） （RT group ）treated by conventional fractionation to a total close of DT66 -70 Gy/6 -7w;chemoradiotherapy group. （50 patients） （CRT group） ： given concomitantly or alternately with RT for 4 -6 courses. The regimen of chemotherapy ; paclitaxel ： 175 mg/（ m2, d ） ,dl, 8 ; cisplatin ; 20 - 50mg （ m^2, d ） , d2 - 5, 4 weeks one circle. Results： Complete response rates of RT and CRT group were 28% and 14. 2% ,respectively; disease progression rates of the two groups were 10% and 16. 3% . The 1 - ,3 - ,5 - year survival rates were 63.2% , 23.6% ,10.2% and 51.8% , 9.2% , 7.4% in CRT and Rt groups （P 〈0.05）. The respective median survivals were 18 months and 12 months , rspectively . （P =0.038）. The CRT group had more obvious side -effect than the RT .group. Conclusion： Concomitant radiotherapy using paclitaxel plus cisplatin can significantly improve the survival rate for stage- Ⅲ non -smal- cell- lung cancer,and its side-effect do not interfere the treatment.
出处
《现代肿瘤医学》
CAS
2006年第12期1525-1527,共3页
Journal of Modern Oncology
